Trials / Completed
CompletedNCT00586495
Long-term Extension From RCC Phase II (11515)
Extension Study for BAY43-9006 in Japanese Patients With Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 95 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Extension to study 11515 (NCT00661375) which was a multicenter study of sorafenib in patients with renal cell carcinoma (RCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib (Nexavar, BAY43-9006) | Sorafenib 200 mg tablets (400 mg \[2 x 200 mg tablets\] twice daily \[bid\] or 400 mg once daily \[od\] or 400 mg every other day \[qod\]) administered orally |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2008-06-01
- Completion
- 2008-07-01
- First posted
- 2008-01-04
- Last updated
- 2013-12-13
- Results posted
- 2010-02-02
Locations
41 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00586495. Inclusion in this directory is not an endorsement.